Cargando…

Comparison of HercepTest™ mAb pharmDx (Dako Omnis, GE001) with Ventana PATHWAY anti-HER-2/neu (4B5) in breast cancer: correlation with HER2 amplification and HER2 low status

Performance of the new CE-IVD-marked HercepTest™ mAb pharmDx (Dako Omnis) assay (HercepTest (mAb)) was compared against the PATHWAY® anti-HER-2/neu (4B5) (PATHWAY 4B5) assay using 119 pre-selected breast cancer samples covering the entire range of HER2 immunohistochemistry (IHC) expression scores (0...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rüschoff, Josef, Friedrich, Michael, Nagelmeier, Iris, Kirchner, Matthias, Andresen, Lena M., Salomon, Karin, Portier, Bryce, Sredni, Simone T., Schildhaus, Hans Ulrich, Jasani, Bharat, Grzelinski, Marius, Viale, Giuseppe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9636083/ https://www.ncbi.nlm.nih.gov/pubmed/35970977 http://dx.doi.org/10.1007/s00428-022-03378-5

Ejemplares similares

Comparison of Dako HercepTest and Ventana PATHWAY anti-HER2 (4B5) tests and their correlation with silver in situ hybridization in lung adenocarcinoma
por: Miladinović, Mirjana, et al.
Publicado: (2021)

HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer
por: Styczen, Hanna, et al.
Publicado: (2015)

An Analytical Comparison of Dako 28-8 PharmDx Assay and an E1L3N Laboratory-Developed Test in the Immunohistochemical Detection of Programmed Death-Ligand 1
por: Cogswell, John, et al.
Publicado: (2016)

Population-based estimate for the correlation of the Oncotype Dx Breast Recurrence Score® result and Ki-67 IHC MIB-1 pharmDx in HR+, HER2−, node-positive early breast cancer
por: Crager, Michael, et al.
Publicado: (2022)

Neue Therapiemöglichkeiten beim metastasierten HER2-low-Mammakarzinom: Konsequenzen für die histopathologische Diagnostik
por: Denkert, Carsten, et al.
Publicado: (2022)

HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing
por: Rüschoff, Josef, et al.
Publicado: (2010)

Physical basis of the ‘magnification rule’ for standardized Immunohistochemical scoring of HER2 in breast and gastric cancer
por: Scheel, Andreas H., et al.
Publicado: (2018)

Immunohistochemical Performance of Estrogen and Progesterone Receptor Antibodies on the Dako Omnis Staining Platform: Evaluation in Multicenter Studies
por: Hicks, David, et al.
Publicado: (2017)

The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
por: Majumder, Avisek, et al.
Publicado: (2021)

HER kinase inhibition in patients with HER2- and HER3-mutant cancers
por: Hyman, David M., et al.
Publicado: (2018)

Combined targeting of HER-2 and HER-3 represents a promising therapeutic strategy in colorectal cancer
por: Conradi, Lena-Christin, et al.
Publicado: (2019)

HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
por: Van Cutsem, Eric, et al.
Publicado: (2014)

Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients
por: Sassen, Andrea, et al.
Publicado: (2008)

HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer
por: Lipton, Allan, et al.
Publicado: (2013)

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
por: Horimoto, Yoshiya, et al.
Publicado: (2022)

HER2/ErbB2 activates HSF1 and thereby controls HSP90 clients including MIF in HER2-overexpressing breast cancer
por: Schulz, R, et al.
Publicado: (2014)

Preclinical HER-2 Vaccines: From Rodent to Human HER-2
por: Lollini, Pier-Luigi, et al.
Publicado: (2013)

HER2 signaling regulates HER2 localization and membrane retention
por: Jeong, Jaekwang, et al.
Publicado: (2017)

Correlation of HER2, p95HER2 and HER3 Expression and Treatment Outcome of Lapatinib plus Capecitabine in her2-Positive Metastatic Breast Cancer
por: Han, Sae-Won, et al.
Publicado: (2012)

Assessment of HER2 testing patterns, HER2+ disease, and the utilization of HER2-directed therapy in early breast cancer
por: Stenehjem, David D, et al.
Publicado: (2014)

HER-3 expression in HER-2-amplified breast carcinoma
por: Czopek, Jacek, et al.
Publicado: (2013)

Model-Based Analysis of HER Activation in Cells Co-Expressing EGFR, HER2 and HER3
por: Shankaran, Harish, et al.
Publicado: (2013)

Statistical modelling of HER2-positivity in breast cancer: Final analyses from two large, multicentre, non-interventional studies in Germany
por: Rüschoff, Josef, et al.
Publicado: (2019)

HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors
por: Spector, Neil, et al.
Publicado: (2007)

Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies
por: Vicario, Rocio, et al.
Publicado: (2015)

HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
por: Ocaña, Alberto, et al.
Publicado: (2020)

Therapeutic Application of Drug-Conjugated HER2 Oligobody (HER2-DOligobody)
por: Kim, Hyun Jung, et al.
Publicado: (2020)

Improving HER2 testing reproducibility in HER2-low breast cancer
por: Sajjadi, Elham, et al.
Publicado: (2022)

HER2/positive and HER2/low in inflammatory breast cancer recurrence
por: Movchan, Oleksii Volodimirovich, et al.
Publicado: (2022)

Loss of HER2 Positivity after Trastuzumab in HER2-Positive Gastric Cancer: Is Change in HER2 Status Significantly Frequent?
por: Ishimine, Yu, et al.
Publicado: (2015)

HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
por: Morsberger, Laura, et al.
Publicado: (2022)

Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
por: Atallah, N. M., et al.
Publicado: (2023)

Intrapatient Tumor Heterogeneity in IHC Interpretation Using PD-L1 IHC 22C3 pharmDx
por: Kalpakoff, Megan, et al.
Publicado: (2021)

Rate of reclassification of HER2-equivocal breast cancer cases to HER2-negative per the 2018 ASCO/CAP guidelines and response of HER2-equivocal cases to anti-HER2 therapy
por: Crespo, James, et al.
Publicado: (2020)

Novel agents that downregulate EGFR, HER2, and HER3 in parallel
por: Ferreira, Renan Barroso, et al.
Publicado: (2015)

Overexpression of HER2/HER3 and clinical feature of ovarian cancer
por: Chung, Ye Won, et al.
Publicado: (2019)

Mutant HER2 needs mutant HER3 to be an effective oncogene
por: Trenker, Raphael, et al.
Publicado: (2021)

Expression of CD24 is associated with HER2 expression and supports HER2-Akt signaling in HER2-positive breast cancer cells
por: Hosonaga, Mari, et al.
Publicado: (2014)

Incidence and prognostic impact of HER2‐positivity loss after dual HER2‐directed neoadjuvant therapy for HER2+ breast cancer
por: LeVee, Alexis, et al.
Publicado: (2023)

Predictive value of quantitative HER2, HER3 and p95HER2 levels in HER2-positive advanced breast cancer patients treated with lapatinib following progression on trastuzumab
por: Duchnowska, Renata, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_rqpntsaahnp42s7eottgmf197g